Oncotelic Therapeutics (OTCQB: OTLC) and its 45%-owned subsidiary, Sapu Nano (US) LLC, announced that the independent Safety Review Committee has completed its review of the initial three-patient safety cohort in the ongoing Phase 1b SP-03-B101 trial of Sapu003. The committee found no dose-limiting toxicities and recommended advancement to the next planned dose level. This milestone supports the continued clinical development of Sapu003, an intravenous formulation of everolimus utilizing the company's Deciparticle nanomedicine platform.
The company also revealed plans to expand the study into Europe with additional clinical sites, aiming to broaden patient access and support enrollment. This strategic move could accelerate the trial's progress and enhance the diversity of the study population. Oncotelic stated that the clinical milestone follows the publication of peer-reviewed research describing the scientific foundation of the Deciparticle platform and the intravenous everolimus formulation Sapu003. The publication highlights the platform's scalable manufacturing capabilities, stability, and preclinical antitumor activity, reinforcing the ongoing clinical development program.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Oncotelic also develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through its relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the platform and ongoing joint development work with TechForce Robotics, Oncotelic's strategic robotics and automation partner.
The positive safety review and European expansion plans represent significant steps forward for Oncotelic's pipeline. For more information, visit the company's newsroom at https://ibn.fm/OTLC. To view the full press release, see https://ibn.fm/sBbID.
